These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

291 related items for PubMed ID: 22019557

  • 1. RGD-based active targeting of novel polycation liposomes bearing siRNA for cancer treatment.
    Yonenaga N, Kenjo E, Asai T, Tsuruta A, Shimizu K, Dewa T, Nango M, Oku N.
    J Control Release; 2012 Jun 10; 160(2):177-81. PubMed ID: 22019557
    [Abstract] [Full Text] [Related]

  • 2. Dicetyl phosphate-tetraethylenepentamine-based liposomes for systemic siRNA delivery.
    Asai T, Matsushita S, Kenjo E, Tsuzuku T, Yonenaga N, Koide H, Hatanaka K, Dewa T, Nango M, Maeda N, Kikuchi H, Oku N.
    Bioconjug Chem; 2011 Mar 16; 22(3):429-35. PubMed ID: 21361311
    [Abstract] [Full Text] [Related]

  • 3. Systemic delivery of small interfering RNA by use of targeted polycation liposomes for cancer therapy.
    Kenjo E, Asai T, Yonenaga N, Ando H, Ishii T, Hatanaka K, Shimizu K, Urita Y, Dewa T, Nango M, Tsukada H, Oku N.
    Biol Pharm Bull; 2013 Mar 16; 36(2):287-91. PubMed ID: 23370357
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Failure of active targeting by a cholesterol-anchored ligand and improvement by altering the lipid composition to prevent ligand desorption.
    Yamamoto S, Sakurai Y, Harashima H.
    Int J Pharm; 2018 Jan 30; 536(1):42-49. PubMed ID: 29126905
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Efficient siRNA delivery and tumor accumulation mediated by ionically cross-linked folic acid-poly(ethylene glycol)-chitosan oligosaccharide lactate nanoparticles: for the potential targeted ovarian cancer gene therapy.
    Li TS, Yawata T, Honke K.
    Eur J Pharm Sci; 2014 Feb 14; 52():48-61. PubMed ID: 24178005
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Targeted delivery of small interfering RNA to angiogenic endothelial cells with liposome-polycation-DNA particles.
    Vader P, Crielaard BJ, van Dommelen SM, van der Meel R, Storm G, Schiffelers RM.
    J Control Release; 2012 Jun 10; 160(2):211-6. PubMed ID: 21983283
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Efficient and Tumor Targeted siRNA Delivery by Polyethylenimine-graft-polycaprolactone-block-poly(ethylene glycol)-folate (PEI-PCL-PEG-Fol).
    Liu L, Zheng M, Librizzi D, Renette T, Merkel OM, Kissel T.
    Mol Pharm; 2016 Jan 04; 13(1):134-43. PubMed ID: 26641134
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.